Australia News
Filter News
Found 6,621 articles
-
Admedus Inks $A36.2M Deal for CardioCel And VascuCel Patch Business
10/14/2019
Admedus Limited (AHZ or the Company) announces the sale of its CardioCel® and VascuCel® patch business to U.S based LeMaitre Vascular Inc. (NASDAQ: LMAT, 'LeMaitre'), for up to $A36.2M ($A22.8M upfront) in cash payments to Admedus.
-
Immuron North American Q1 Sales Up 111% YoY
10/14/2019
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens, is pleased to announce sales results for its commercially available, over-the-counter gastrointestinal and digestive health supplement Travelan®, for the quarter ended September 30, 2019, of fiscal year 2020 (Q1).
-
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal
10/14/2019
YONDELIS® (trabectedin) is a globally recognised treatment for patients with advanced soft tissue sarcoma as second-line therapy and beyond, but has been difficult for Australians to access
-
Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco
10/14/2019
Opthea Limited announced that additional data analyses from the recently completed 366 patient Phase 2b randomised, controlled wet AMD study of OPT-302 with ranibizumab compared to ranibizumab alone, was presented at the Ophthalmology Innovation Summit in San Francisco.
-
Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging
10/13/2019
Telix Pharmaceuticals Limited announced the completion of the integration of GE Healthcare’s cyclotron-based 68Ga production data with Telix’s regulatory package for TLX591-CDx for the imaging of prostate cancer with Positron Emission Tomography.
-
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
10/10/2019
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €1,568,399 (~ A$2,546,929) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).
-
Immutep Announces Data Presentations at Upcoming Industry Conferences
10/10/2019
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019.
-
Recce Completes Raising of AU$6.76 million
10/10/2019
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
-
Scenesse is an under-the-skin implant. The drug is the company’s only approved product.
-
Sean Hart Named Chief Business Officer of George Clinical
10/9/2019
Hart, who joined George Clinical through the acquisition of Vector Oncology in 2017, will now lead business development functions globally for the organization.
-
Zelda Therapeutics to Webcast Live at VirtualInvestorConferences.com October 10th
10/9/2019
Zelda Therapeutics (ASX:ZLD), a Australian-based biotech recently announced a merger with US-based Ilera Therapeutics creating a leading globally-integrated company developing clinically validated medicinal cannabis product
-
Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd
10/9/2019
The Board of AdAlta Limited, is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director.
-
Physitrack - Independent Scientific Study Proves Significant Positive Impact on Patient Journey
10/7/2019
The world-leading Department of Physiotherapy of the University of Melbourne, Australia, has published a multi-year, independent scientific study of exercise adherence among patients recovering from orthopaedic injuries in the American Journal of Physical Medicine & Rehabilitation.
-
Aroa Biosurgery Grows Into Additional Markets With Positive Outcomes From Canadian Clinical Study
10/3/2019
Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive outcomes of a new clinical study in Canada performed using its core wound product Endoform Natural®, which is being launched in the Canadian market along with Endoform Antimicrobial® in October 2019.
-
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US
10/2/2019
Mayne Pharma is pleased to announce it has entered into an exclusive license and supply agreement with Mithra to commercialise E4/DRSP, a combined oral contraceptive, in the United States.
-
Former Innate Immunotherapeutics Board Member Chris Collins Expected to Plead Guilty to Insider T...
10/1/2019
On Monday, the House Republican resigned his congressional seat ahead of the expected plea. -
The University of Queensland Uses Dell Technologies Supercomputer to Pioneer New Alzheimer's Disease Breakthrough
10/1/2019
Dell Technologies announces one of the first computational projects for The University of Queensland's Dell Technologies high-performance computing (HPC) system may enable a non-invasive disease-modifying strategy for Alzheimer's Disease.
-
Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress
10/1/2019
Imugene Limited, a clinical stage immuno-oncology company, announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti-cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
-
European Society of Medical Oncology Congress Presentations Show B-Cell Vaccine Combinations Inhibit Cancer Growth in Preclinical Models
10/1/2019
Imugene Limited announced two presentations by medical investigators at the European Society of Medical Oncology in Barcelona Spain showed combining its HER2 vaccines with PD1 vaccines reduced cancer growth in a number of standard preclinical models.
-
AVITA Medical Announces Listing on Nasdaq
9/30/2019
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st